ReviewCancer prevention research (Philadelphia, Pa.)2012
The state of molecular biomarkers for the early detection of lung cancer.
Review in Cancer prevention research (Philadelphia, Pa.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 3 syntheses or guidelines pooled it, 214 citations in OpenAlex.
- Nanoparticle trends and hotspots in lung cancer diagnosis from 2006-2023: a bibliometric analysis.Frontiers in oncology · 2024Pooled it
- Volatile Organic Compounds in Human Exhaled Breath to Diagnose Gastrointestinal Cancer: A Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Pooled it
- Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.The Journal of clinical investigation · 2021Trial
- BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Trial
- Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer.BioMed research international · 2014Trial
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- LncRNA MANCR is downregulated in non-small cell lung cancer and predicts poor survival.Discover oncology · 2025Article
- Salivary biomarkers in cancer detection and management.Acta biochimica Polonica · 2025Review
- Multi-omics model is an effective means to diagnose benign and malignant pulmonary nodules.Clinics (Sao Paulo, Brazil) · 2025Article
- Article
- Periodontal Molecular Diagnostics: State of Knowledge and Future Prospects for Clinical Application.International journal of molecular sciences · 2024Review
- Plasma exosomes contain protein biomarkers valuable for the diagnosis of lung cancer.Discover oncology · 2024Article
- Salivary metabolomic biomarkers for non-invasive lung cancer detection.Cancer science · 2024Article
- Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings.PloS one · 2024Article
- Combining Low-Dose Computer-Tomography-Based Radiomics and Serum Metabolomics for Diagnosis of Malignant Nodules in Participants of Lung Cancer Screening Studies.Biomolecules · 2023Article
- A novel multimodal prediction model based on DNA methylation biomarkers and low-dose computed tomography images for identifying early-stage lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- ESOMIR: a curated database of biomarker genes and miRNAs associated with esophageal cancer.Database : the journal of biological databases and curation · 2023Article
- Metabolic biomarkers in lung cancer screening and early diagnosis (Review).Oncology letters · 2023Review
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Using biomarkers to select the most at-risk population, to detect the disease while measurable and yet not clinically apparent has been the goal of many investigations. Recent advances in molecular strategies and analytic platforms, including genomics, epigenomics, proteomics, and metabolomics, have identified increasing numbers of potential biomarkers in the blood, urine, exhaled breath condensate, bronchial specimens, saliva, and sputum, but none have yet moved to the clinical setting. Therefore, there is a recognized gap between the promise and the product delivery in the cancer biomarker field. In this review, we define clinical contexts where risk and diagnostic biomarkers may have use in the management of lung cancer, identify the most relevant candidate biomarkers of early detection, provide their state of development, and finally discuss critical aspects of study design in molecular biomarkers for early detection of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.